Acasă › Limfom Burkitt › California

Studii clinice pentru Limfom Burkitt în California

20 studii pentru Limfom Burkitt caută participanți în California.

Orașe în California

Text oficial al studiului (în engleză)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Kaiser Permanente Downey Medical Center, Downey
Loma Linda University Medical Center, Loma Linda
Miller Children's and Women's Hospital Long Beach, Long Beach
și încă 9

În curs de recrutareFaza 2

366 Days – 46 Years · Toate sexele · Actualizat 2 oct. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Kaiser Permanente-Deer Valley Medical Center, Antioch
Community Cancer Institute, Clovis
UC Irvine Health Cancer Center-Newport, Costa Mesa
și încă 26

În curs de recrutareFaza 3

Vârste de la 18 la 39 · Toate sexele · Actualizat 2 oct. 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

City of Hope Comprehensive Cancer Center, Duarte
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC San Diego Moores Cancer Center, La Jolla
și încă 1

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 29 sept. 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Loma Linda University Medical Center, Loma Linda
Miller Children's and Women's Hospital Long Beach, Long Beach
UCSF Benioff Children's Hospital Oakland, Oakland
și încă 4

În curs de recrutareFaza 2

365 Days · Toate sexele · Actualizat 25 sept. 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

UC Irvine, Orange

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 21 sept. 2026 · NCT07648264

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Children's Hospital Los Angeles ( Site 1006), Los Angeles

În curs de recrutareFaza 1/2

6 Months – 25 Years · Toate sexele · Actualizat 17 sept. 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Kaiser Permanente-Anaheim, Anaheim
Kaiser Permanente Downey Medical Center, Downey
Kaiser Permanente-Fontana, Fontana
și încă 14

În curs de recrutareFaza 2

Vârste de la 1 la 30 · Toate sexele · Actualizat 1 sept. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Kaiser Permanente Downey Medical Center, Downey
City of Hope Comprehensive Cancer Center, Duarte
Loma Linda University Medical Center, Loma Linda
și încă 14

În curs de recrutareFaza 3

365 Days – 25 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Children's Hospital Los Angeles, Los Angeles
Children's Hospital Orange County, Orange
UCSF School of Medicine, San Francisco

În curs de recrutareFaza 2

Vârste de la 7 la 25 · Toate sexele · Actualizat 19 aug. 2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Research Site, Duarte
Research Site, Los Angeles
Research Site, Palo Alto

În curs de recrutareFaza 1/2

Vârste de 12 ani și peste · Toate sexele · Actualizat 19 aug. 2026 · NCT06137118

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University, Palo Alto

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 12 aug. 2026 · NCT06340737

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

În curs de recrutareFaza 1/2

Vârste de la 13 la 90 · Toate sexele · Actualizat 6 aug. 2026 · NCT06533579

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 31 iul. 2026 · NCT07069699

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

City of Hope Medical Center, Duarte

În curs de recrutareFaza 1

Vârste de la 12 la 55 · Toate sexele · Actualizat 14 iul. 2026 · NCT07133997

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Research Site, Duarte

În curs de recrutareFaza 1/2

Vârste de 12 ani și peste · Toate sexele · Actualizat 13 iul. 2026 · NCT07109219

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 22 iun. 2026 · NCT04545762

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine
UC San Diego Moores Cancer Center, La Jolla
și încă 1

În curs de recrutareFaza 2

Vârste de la 18 la 54 · Toate sexele · Actualizat 17 mar. 2026 · NCT06918431

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

City of Hope, Duarte

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 5 nov. 2025 · NCT04260022

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

University of California, Los Angeles (UCLA) - Medical Center, Los Angeles

În curs de recrutareFaza 1/2

Vârste de la 15 la 50 · Toate sexele · Actualizat 9 sept. 2025 · NCT04150497

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

City of Hope, Duarte
Children's Hospital Los Angeles, Los Angeles
UCLA Mattel Children's Hospital, Los Angeles
și încă 2

În curs de recrutareFaza 2

Vârste de la 1 la 25 · Toate sexele · Actualizat 4 mai 2025 · NCT03509961

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.